17 results about "Local injection" patented technology

This invention relates to a locally injectable hydrogel for treating pancreatic cancer, its preparation method, and its application. The hydrogel is prepared from raw materials comprising hyaluronic acid-dopamine and a radionuclide. Through extensive research and optimization, this invention has discovered that reacting hyaluronic acid-dopamine and a radionuclide in a suitable temperature and solvent, followed by mixing the resulting reaction solution with an alkaline sodium periodate solution and rapid stirring, successfully prepares a locally injectable hydrogel highly suitable for treating pancreatic cancer. The hydrogel is prepared under mild conditions, has a simple composition, and high safety. It effectively addresses the core bottlenecks in local radiotherapy for pancreatic cancer, such as poor stability of radionuclide carriers, short retention time, and uncontrollable release. Furthermore, it can reshape the body's immune microenvironment and enhance anti-tumor immune responses, significantly improving therapeutic efficacy. This has significant clinical implications for overcoming the current limitations in the treatment of locally advanced unresectable pancreatic cancer.

The invention relates to the technical field of biomedicine and pharmacy, and discloses application of polypeptide in preparation of a medicine for treating and / or preventing depression. An IL-33 / ST2 signal channel in an LS brain region is a key endogenous protection mechanism for maintaining normal emotion, and by constructing a CSDS depression mouse model for verification, the 81st-95th amino acid sequence of the IL-33 protein is determined to be a core active fragment of the IL-33 protein combined with an ST2 receptor and exerting an anti-depression function. Experiments prove that no matter through intraperitoneal injection or LS brain region local injection, the polypeptide can significantly improve mouse depression-like behaviors induced by a CSDS or LPS model. The polypeptide provided by the invention is small in molecular weight, can pass through a blood brain barrier after being fused with TAT, and provides important candidate molecules and treatment strategies for developing novel and effective antidepressant drugs.

The application discloses application of serine or a pharmaceutically acceptable salt thereof in preparation of a medicine for preventing or treating intervertebral disc degeneration, and a medicine composition containing the active ingredient, and belongs to the technical field of biological medicine. The application takes serine as the active ingredient, provides application of the serine in preparation of the medicine for treating intervertebral disc degeneration, the medicine can supplement serine exogenously, corrects redox imbalance of nucleus pulposus cells, reverses cell aging, and thus can improve the intervertebral disc degeneration process. The application further provides a corresponding medicine composition, which can be prepared into a local injection preparation or an oral preparation, wherein the local injection preparation can be combined with a biomaterial to construct a slow-release delivery system, so that long-acting targeted drug delivery is achieved.

An injectable bifunctional hydrogel has antibacterial activity. The bifunctional hydrogel is a hydrogel prepared by dissolving nucleoside analogues in a solvent. The nucleoside analog has a structure of formula I. It can be a candidate drug for the local injection treatment of periodontal disease, and it also has potential application prospects in the minimally invasive treatment of craniofacial bone tissue defects.

The invention discloses a PDGFD derived peptide as well as a preparation method and application thereof. The invention designs and synthesizes a PDGFD derived peptide. A verification result shows that the PDGFD derived peptide can significantly promote the two-way differentiation of dentin formation and vascularization of dental pulp mesenchymal stem cells. The derivative peptide disclosed by the invention has the advantages of small molecule, high stability, strong binding force and easiness in synthesis. The synthesized polypeptide provides a novel peptide medicine for tooth regeneration, can be applied to stem cell culture, tissue engineering scaffolds, local injection preparations and the like, improves the regeneration efficiency, and has wide application prospects in the fields of tooth regeneration, dental pulp repair, osteoporosis and other hard tissue regeneration.

The invention discloses application of NAC in preparation of a medicine for treating temporomandibular joint disorder, and particularly discloses application of the medicine in effectively improving TMD joint tissue oxidation resistance, inhibiting inflammation level, promoting extracellular matrix secretion and inhibiting iron (ferrous) ions and lipid peroxides so as to improve cartilage injury, relieve pain in a condylar process region and improve osteoarthritis. As a clinical common medicine, NAC is low in cost, high in availability, excellent in cell and tissue safety and high in practicability. The medicine can be safely applied to TMD treatment by means of condyle local injection or condyle region skin application (microneedle) and the like, has important significance in clinical medication of TMD, and has good medication value and application prospect.

The invention discloses a composition for promoting skeletal muscle injury regeneration and application thereof, and belongs to the technical field of medicines. In order to solve the technical problems that in the prior art, the skeletal muscle injury regeneration promotion effect of nutrients is insufficient, and the new application of eleutheroside B in the field is undefined, the invention provides a composition for promoting skeletal muscle injury regeneration, and the composition effectively shortens the regeneration time of skeletal muscle after chemical injury or mechanical injury and improves the skeletal muscle regeneration effect. The maturity of new muscle fibers is improved; the composition can be in oral dosage forms such as instant powder, oral liquid or tablets, can take effect on the day of injury, does not need local injection, is convenient to use, and is suitable for preparing functional food or formula food for special medical purposes for shortening the regeneration time of skeletal muscle after injury and improving the maturity of new muscle fibers. And a new technical scheme is provided for nutrition intervention of skeletal muscle injury.

The invention discloses an extracellular vesicle for treating facial nerve injury and a preparation method thereof. The hNSCs-EVs are separated from an hNSCs conditioned culture medium through an ultracentrifugation method, the particle size of the hNSCs-EVs is 100-150nm, and the hNSCs-EVs express CD9, CD63 and TSG101 markers. Experiments prove that when hNSC-EVs is locally injected to the injured part of facial nerves, functional recovery of the facial nerves can be remarkably promoted, electrophysiological signals can be improved, and axon regeneration, myelin sheath formation and Schwann cell activation can be effectively promoted. The invention provides a brand new treatment strategy which is safe, effective, easy to store and standard for facial nerve injury, and has a wide clinical application prospect.

The application discloses a kind of customized analgesic hydrogel and its preparation and application.Specifically, the application discloses a new analgesic target, screens suitable drugs, and according to the characteristics of drug molecules, two-step method is customized to obtain sustained-release analgesic hydrogel.The two-step method is specifically divided into the following: first, according to the structure of drug molecules, aldehyde-based hyaluronic acid is synthesized to realize chemical drug loading;Second, adjust the concentration of Schiff base to form a double grid environment to realize injectability.Load the inhibitory drug TAPI-1 for the new target ADAM17 of stomatognathic inflammatory pain, construct a drug delivery system with targeted delivery, sustained-release analgesia, local injection and long-acting effect.Compared with the prior art, the drug delivery system obtained by the application has excellent sustained-release performance, the prolonged drug release is consistent with the hyperalgesia window period of stomatognathic inflammatory pain, precise and effective pain management is achieved, and the operation is simple, and has good conversion application prospect.

A leakage inhibiting agent includes a gelatin hydrolysate having a weight average molecular weight of 5000 or less, wherein a degree of viscosity at 25°C of a first solution obtained by dissolving the gelatin hydrolysate in phosphate buffered saline and adjusting the concentration of the gelatin hydrolysate to 40% by mass is 20 mPa s or less.

This invention provides an injectable meloxicam, its preparation method, and its uses. The injectable formulation comprises meloxicam, an external aqueous phase, and liposomes. The liposomes contain an internal aqueous phase, which is a salt solution containing metal ions. The meloxicam can form an insoluble salt with the metal ions and be stably loaded in the aqueous phase within the liposomes. This injectable formulation has a high drug loading capacity and good storage stability. After intravenous injection into the bloodstream, it can rapidly release the drug to exert an analgesic effect. It can also be used for local injection in joint cavities to improve local analgesia and anti-inflammatory effects and reduce the dosage required for systemic administration.

The utility model relates to the technical field of medical treatment, and discloses an injector which comprises a needle shell, an injection needle, a driving unit and a detection unit. The injection needle is arranged at one end, close to injection skin, of the needle shell and has a first state of being arranged in the needle shell and a second state of extending out of the needle shell; the driving unit is used for driving the needle shell to move in at least two directions; the detection unit is arranged on the needle shell and used for forming a subcutaneous image when the injection needle is in the first state. By arranging the detection unit, the subcutaneous medicine exosmosis range of the patient can be detected in real time, and medical staff with less experience can accurately find the position of injection of the local sealing liquid according to the medicine exosmosis range. When the local sealing liquid is injected, a medical worker adjusts the position of the injection needle through the driving unit, and the injection angle of the injection needle can be adjusted in real time. On the basis, the injection of the local sealing liquid can be operated by medical staff with less experience, so that the technical effect of reducing the pressure of medical resources is achieved.

The invention discloses a hypertonic muscle injection for an immune wake-up therapy and a preparation method of the hypertonic muscle injection, and relates to the medical field, the injection is hypertonic glucose with the concentration of 15-25%, and is only composed of anhydrous dextrose and water for injection; the injection is used for intramuscular injection, anatomical local injection, traditional Chinese medicine acupoint injection and focus part injection based on a targeting principle, and intravenous injection is strictly prohibited; compared with the prior art, the invention has the beneficial effects that controllable micro-injury is caused by the hypertonic glucose or sodium chloride injection, the central immune system is awakened, lesions are automatically cleared by autoimmunity, various diseases can be treated at the same time, and the defect of single target spot is overcome; the preparation only consists of sugar / salt and water for injection, and has no toxic or side effect and no drug resistance; raw materials are easy to obtain, the process is simple, cost is extremely low, and patient burden is remarkably relieved; the medicine is simple and convenient to operate, wide in adaptation disease, capable of being combined with any existing therapy and extremely high in clinical value.

The disclosure provides an injectable pharmaceutical formulation comprising tirbanibulin, in free or pharmaceutically acceptable salt form, for local injection to treat cancerous, precancerous and proliferative conditions of the skin, together with injection devices and methods of treatment.

The invention provides an interventional drug delivery device for the heart. The interventional drug delivery device comprises an outer sleeve and an inner sleeve, and the inner sleeve is arranged in the outer sleeve in a sleeved mode; the spiral electrode is arranged at the far end of the outer sleeve; the ring electrode is arranged on the outer sleeve and is close to the near end of the outer sleeve; the electrode wire is connected with the spiral electrode and the ring electrode, and is positioned between the outer sleeve and the inner sleeve; and the injection needle is positioned at the far end of the outer sleeve and is communicated with the inner sleeve. The device has an intracavity icon measurement function and a local injection administration function, a heart conduction bundle and depth can be positioned through intracavity icon measurement of the spiral electrode, the device can be used for treatment of an injection needle on the conduction bundle or avoidance of the conduction bundle during treatment, and a target part can be accurately positioned for treatment; the defect that the deep part of the chamber wall cannot be ablated through radiofrequency ablation and the defect that conduction bundles are damaged in the outflow tract dredging operation of the cardiac surgery are overcome.

The use of a mitoxantrone preparation in the preparation of a drug for diagnosing and treating breast cancer. Provided is the use of mitoxantrone and / or a pharmaceutically acceptable salt thereof in the preparation of a lymphatic tracer in a disease associated with breast resection. No local or systemic toxic and side effects are seen after local injection of the preparation, suggesting that the preparation has good tolerance, effectiveness and safety, which provides a new treatment idea for thoroughly curing breast cancer in a breast cancer patient.

A treatment device and an endoscopic treatment method are disclosed. The treatment device includes a first pipeline that is made of material having electrical insulation, and includes an internal space; an electrode that is energizable with high frequency current; a distal-end tip that is attached to a distal end of the first pipeline, and includes a distal-end opening in communication with the internal space of the first pipeline; and a second pipeline that is inserted through the first pipeline and through which liquid can pass. The endoscopic treatment method includes puncturing a treatment target and performing a local injection using the treatment device.